We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-4.14%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$222M
AUM Growth
+$7.51M
Cap. Flow
+$26.6M
Cap. Flow %
11.96%
Top 10 Hldgs %
87.78%
Holding
26
New
1
Increased
7
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$34.2M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$12.4M
3
APEN
Apollo Endosurgery, Inc.
APEN
+$3.72M
4
EOLS icon
Evolus
EOLS
+$2.12M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$2.12M

Top Sells

Rank Stock Value
1
CSTL icon
Castle Biosciences
CSTL
+$6.48M
2
ADMA icon
ADMA Biologics
ADMA
+$4.8M
3
OVID icon
Ovid Therapeutics
OVID
+$4.07M
4
AFMD
Affimed
AFMD
+$3.24M
5
DMAC icon
DiaMedica Therapeutics
DMAC
+$2.38M

Sector Composition

Rank Sector Weight
1 Healthcare 98.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
26
DELISTED
Aerie Pharmaceuticals
AERI
– –
-251,235
Closed -$1.88M
1
2

Similar funds

ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Stonepine Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Stonepine Capital Management held 26 positions worth $222M, up 3.5% from $215M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Stonepine Capital Management deployed $26.6M of net new capital in Q3 2022, opening 1 new position and adding to 7 existing holdings. Its largest new stake was Evolus: 200,000 shares worth $1.61M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was ADMA Biologics, an estimated $4.8M trimmed.

  • Stonepine Capital Management's largest Q3 2022 buy was Evolus: 200,000 shares worth $1.61M.
  • Stonepine Capital Management added most to QuidelOrtho in Q3 2022, an estimated $34.2M increase.
  • Stonepine Capital Management's biggest Q3 2022 reduction was ADMA Biologics, cutting an estimated $4.8M.
  • Stonepine Capital Management fully exited Castle Biosciences in Q3 2022, selling an estimated $6.48M.
  • Stonepine Capital Management's ten largest holdings make up 88% of its $222M portfolio in Q3 2022.
  • Stonepine Capital Management opened 1 new position and closed 7 in Q3 2022.
  • Stonepine Capital Management's portfolio value rose 3.5% quarter-over-quarter to $222M.

Based on Stonepine Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.